56 results about "Drug application" patented technology

The invention discloses an antibody as well as a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenem enzyme, and can reduce the carbapenem drug resistance level of the acinetobacter baumannii, so that the clinical use concentration of meropenem is reduced, and the treatment effect of meropenem on the acinetobacter baumannii is improved. In addition, the antibody disclosed by the invention can also inhibit OXA-23 protein secreted by bacteria, prevent the bacteria from hydrolyzing carbapenem antibiotics, increase the concentration of antibiotics in a medication part, and facilitate the removal of mixed infection with acinetobacter baumannii. The invention provides a new strategy for treating acinetobacter baumannii infection, and the application prospect is wide.

The present application belongs to the technical field of hair loss treatment, and particularly relates to a phototherapy and drug synergistic intervention system for androgenetic alopecia of human scalp. In the system, the drug is angelica extract with a concentration of 0.1-500 ug / mL; the phototherapy light source is a red light LED light source with a wavelength of 600-700 nm; the light irradiance is 2-100 mW / cm 2 ; the light dose is 2-20 J / cm 2 ; the irradiation mode is steady light or pulsed light; and the synergistic intervention mode is that the phototherapy and the drug application are performed synchronously or the phototherapy is performed within 0.5-2 hours after the drug application. Experiments show that the light-drug combined intervention significantly improves cell viability, ATP level, migration ability, IGF1 and VEGF secretion, reduces ROS and MDA levels, inhibits Caspase-3 activity, regulates BCL2 / BAX expression, activates Wnt, Hh and PI3K pathways, and inhibits BMP and TGF-beta pathways. The present application provides a treatment scheme with clear timing and standardization, and realizes safe, non-invasive and efficient hair loss treatment.

The invention belongs to the technical field of biotechnology, and particularly relates to application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit and a detection method. The invention provides an application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit for liver cirrhosis diagnosis / treatment and a detection method of a serum exosome MZF1 protein. The exosome MZF1 protein is used as a marker, a valuable reagent or drug application prospect is provided for early diagnosis and treatment of liver cirrhosis, and help is provided for analysis of more serum exosome proteins applied to liver cirrhosis markers.

The application discloses a method for calculating the area of pesticide application. The method comprises the following steps: obtaining the motion trajectory of a pesticide application device, and intercepting a third trajectory located in a first area to be applied with pesticide; obtaining a radiation range according to the third trajectory and the pesticide application range, and performing color processing; calculating the area after color processing to obtain the pesticide application area, and judging the pesticide application condition in combination with a target area. In addition, after the pesticide application is completed, a trajectory point is randomly selected as a detection position, and a corresponding plant image is required to be uploaded for verification. The application solves the area calculation problem of irregular areas and overlapping spraying through a color algorithm, and realizes precise quantitative evaluation and anti-fraud supervision of the pesticide application quality in combination with a random inspection mechanism.

The invention belongs to the technical field of immunology, and discloses an anti-human CD19 receptor single-domain antibody, and the amino acid sequence of the single-domain antibody is as shown in SEQ ID No.1. The antibody has good reaction activity with human CD19, can be used for detecting or diagnosing CD19 and treating related diseases with abnormal CD19 expression, and has wide application prospects in the fields of drug application, clinical detection and diagnosis and the like.

This invention discloses a preparation process for a homogeneous immunomodulatory polysaccharide from *Gynostemma pentaphyllum* and its application in the preparation of anti-melanoma drugs and immunomodulators, relating to the field of pharmaceutical manufacturing technology. The preparation process includes four steps: compound enzyme-ultrasound synergistic extraction, fractional alcohol precipitation to remove proteins, DEAE-52 ion exchange column chromatography, and Sephacryl S-400 gel permeation chromatography purification. The resulting homogeneous polysaccharide (GOP-3) has a weight-average molecular weight of 12±1 kDa and is composed of mannose, glucose, and galactose in a specific ratio. The GOP-3 of this invention has a weight-average molecular weight (Mw) of 12.8 kDa, a dispersion (Mw / Mn) < 1.2, a uronic acid content of 23.5%, a well-defined structure, and is suitable for drug application. Furthermore, GOP-3 can significantly promote the secretion of IL-12 by dendritic cells and induce the differentiation of naive T cells into Th1 cells. Simultaneously, compared with a full-dose PD-1 monoclonal antibody, the combination of GOP-3 and a half-dose monoclonal antibody not only reduces the risk of immune-mediated pneumonia caused by antibody drugs but also increases the tumor inhibition rate by more than 40%.

The application relates to application of C-methylated high isoflavone compounds in preparation of antitumor drugs and belongs to the technical field of drug application. In order to solve the problem that the existing antitumor activity is not much reported, the application of C-methylated high isoflavone compounds in preparation of antitumor drugs is provided, the C-methylated high isoflavone compounds are selected from compounds shown in the following formula 1 or formula 2: the C-methylated high isoflavone compounds or pharmaceutically acceptable salts thereof are used as active ingredients for preparation of antitumor drugs for preventing and / or treating adrenal pheochromocytoma (PC-12) and / or human brain astrocytoma (U-87MG). The C-methylated high isoflavone compounds have the advantages of high activity and high inhibition capacity, can be extracted from polygonatum sibiricum and have good drug safety.

The invention relates to the technical field of biological medicines, and particularly discloses a high-grade serous ovarian cancer (HGSOC) treatment strategy based on ANXA6 protein detection and regulation. The invention provides a method for evaluating the sensitivity of a patient to cisplatin chemotherapy by detecting the expression level of ANXA6 protein or a specific modification site thereof, and a composition comprising inhibiting the function of ANXA6 or combining with cisplatin. In addition, the invention also relates to a medicine application for enhancing the chemotherapy effect by regulating the activity of ANXA6 related modifying enzyme.

The invention relates to an aquacide microsphere preparation and a preparation method thereof, aquacide is entrapped in a polylactic acid-glycolic acid copolymer carrier through a W / O / W type re-emulsification-solvent evaporation method, the microsphere preparation is prepared, slow and continuous release of drugs can be realized, the lasting period is prolonged, the drug application frequency is reduced, and the drug wastage rate and the environmental risk are reduced; meanwhile, the pesticide is in a solid state, is suitable for long-distance transportation, can be redissolved before being used, and has important practical application and commercial values.

The application discloses a kind of saving type synchronous oiling and dosing methods for drug application unmanned aerial vehicle, including two feeding nozzles arranged on the material adding unmanned aerial vehicle and drug application oil tank and drug application tank arranged on the drug application unmanned aerial vehicle;The structure of drug application oil tank and drug application tank is same, and it includes box, leakage-proof sealing film, one-way pressure door and liquid leakage collection box;Feeding nozzle includes outer tube and inner tube arranged in outer tube, and the end of outer tube is inserted into the through hole of liquid leakage collection box after passing through the flow channel, and the open end of inner tube faces automatic telescopic structure, and automatic telescopic structure drives automatic support mechanism to extend into the inner side of inner tube, and after electric support mechanism drives the support claw of itself to open, it is supported on the inner wall of inner tube;The application solves the problem that the existing drug application unmanned aerial vehicle repeatedly lifts to add oil and medicine, resulting in low work efficiency, and the problem of supply waste and environmental pollution caused by material leakage when the material adding unmanned aerial vehicle supplies the drug application unmanned aerial vehicle in the air.

The invention discloses a compound serving as an AKR1C3 (aldoketoreductase 1C3) inhibitor as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The compound has a structure shown in a formula I or a pharmaceutically acceptable salt thereof; wherein when R1 is carboxyl, A is a nitrogen-containing saturated aromatic ring, and B is an unsaturated aromatic ring or an unsaturated heterocyclic ring; when R2 is carboxyl, B is an unsaturated aromatic ring, and A is a condensed ring containing a nitrogen-containing saturated aromatic ring. The piperidinecarboxylic acid compound or benzoic acid compound and the pharmaceutically acceptable salt thereof provided by the invention can selectively inhibit the activity of AKR1C3, have a remarkable inhibition effect, achieve the effect of preventing and treating prostatic cancer through a final step of inhibiting the generation of androgen in tumor cells, can be prepared into a medicine for treating AKR1C3 related diseases, and have a wide application prospect. Particularly, the compound is applied to preparation of a medicine for treating prostatic cancer. Formula I.

The application relates to a dihydropyridine small-molecule compound and a preparation method and application thereof in preparing a drug for treating neuroblastoma, and belongs to the technical field of drug preparation. The application discloses a dihydropyridine small-molecule compound, a structural formula of which is as shown in the description, which can be used for preparing a drug for treating neuroblastoma with high ALDH18A1 expression, can effectively solve the problems of poor water solubility of YG1702, low inhibition rate of neuroblastoma and other drug application problems, and has a good application prospect.

The invention discloses a vagina medicine applying device for gynecological patients. The vagina medicine applying device comprises a pulling medicine applying device and a clamping pushing component. The invention belongs to the field of medical instruments, and particularly relates to a vagina medicine applying device for gynecological patients. The device serves as a gynecological vagina local drug delivery instrument, through optimization of a mechanical structure and integration of functions, technology upgrading and function innovation of a traditional vagina applicator are achieved, the industry current situation that a traditional gynecological drug application instrument is single in function and extensive in operation is broken through, triple improvement of the treatment effect, the use experience and the operation safety is achieved, and the device is worthy of popularization and application. A more efficient, safer and more humanized dosing tool is provided for gynecological clinical nursing, and the overall service quality of gynecological nursing can be improved.

This utility model discloses a drug application spraying device for applying medicine to the surface of a yak, including a handheld handle with several spray tubes arranged side by side at one end and a medicine inlet tube at the other end; a roller rotatably mounted on the outer side of the end of the spray tubes, with its axis parallel to the arrangement direction of the spray tubes; the end of each spray tube has an axially movable ball head. When the end of the spray tube contacts the yak's surface, the ball head is pressed and retracts into the tube, opening the spray passage; when the pressure is released, the ball head returns to its original position and presses against the sealing surface of the end of the spray tube, closing the spray passage. This spraying device, through the several spray tubes at the end of the handheld handle, allows for easy contact with the yak's surface and penetration into the hair, pushing the ball head back into the spray tube to achieve drug application. This avoids the problem of the medicine not being able to penetrate the hair and contact the surface during long-distance spraying. Furthermore, the roller can roll on the yak's surface, ensuring uniform application of the medicine.

The invention discloses polygalacturonic acid (PGA) and application of a neohesperidin dihydrochalcone (NHDC) or neohesperidin (NH) embedded compound of the polygalacturonic acid (PGA) in preparation of anti-allergic food or drugs. The PGA has good biocompatibility and immune regulation and intestinal barrier repair functions. Experiments show that the PGA can significantly reduce IgE-mediated food anaphylaxis, alleviate allergic symptoms and improve intestinal structures. PGA is adopted as a carrier, and the PGA and NHDC / NH form non-covalent binding through intermolecular force to prepare the PGA-NHDC / PGA-NH compound, so that the solubility and the stability of the NHDC / NH are improved, and a synergistic anti-allergic effect is also generated. The PGA-NHDC / PGA-NH compound has the advantages of small molecular weight, fast absorption and non-immunogenicity, and can release NHDC / NH in colon in a targeted manner. On the basis, the invention further provides the application of the PGA-NHDC / PGA-NH compound in preparation of the orange juice, the obtained juice system is in a stable suspension state, has no precipitation layering phenomenon, has targeted synergistic antianaphylaxis and high storage stability, and remarkably improves the functionality and the storage stability of the juice.

1. Name of the product in this design: Drug uniform application device. 2. Purpose of this design: This design is a drug application device for evenly applying ointments or drugs to the affected area. 3. The key design features of this product are its overall shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

The invention belongs to the technical field of pesticide disinfestation, and discloses an insecticidal composition and application thereof.The insecticidal composition comprises an active component A and an active component B. The active component A is a compound shown in the formula I (formula I), and the active component B is any one of a compound shown in the formula II (formula II) or a compound shown in the formula III (formula III); the mass ratio of the active component A to the active component B is (1: 50)-(50: 1). According to the insecticidal composition disclosed by the invention, insecticides with different action mechanisms are compounded to form a complementary effect, so that the control effect is improved, the adaptation difficulty of pests can be increased, and the development of drug resistance is delayed. Through compounding, multiple treatment effects can be realized by one drug, and the drug application frequency is reduced.

This invention relates to the field of deep-sea mining hose cleaning technology, specifically to an intelligent robot and method for cleaning adsorbed organisms on deep-sea mining hoses. The robot includes two shells, with a power storage compartment inside each shell for storing power. It also includes a visual drug application device for monitoring bioadsorption on the mining hose and performing preliminary drug treatment, a vortex-flow erosion device for further treatment of adsorbed organisms, a positioning and detection device for monitoring the treated mining hose, treating stubborn residual adsorbents, and monitoring the overall condition of the mining hose, an AUV thruster, and a communication control device. The communication control device includes an ACN underwater acoustic communication module and an intelligent processing module. The invention also includes a cleaning method using this robot. This application features multi-level collaborative cleaning, significantly improving the efficiency of bioadhesion removal, intelligent closed-loop control, and fully autonomous operation, reducing labor costs.

The invention discloses an application of an NAT10-ac4C-mitochondrial-acetyl-CoA regulation axis in diagnosis and treatment of mitochondrial dysfunction and related metabolic diseases, and belongs to the technical field of biology. The regulatory axis systematically regulates the expression of the nuclear coding mitochondrial gene in a physiological state, and maintains a metabolism steady state; the invention also provides a biomarker combination of the regulatory axis. The biomarker combination comprises NAT10 related indexes, ac4C modification level of nuclear coding mitochondrial gene mRNA and acetyl coenzyme A level, and can be used for diagnosis and prognosis evaluation of mitochondrial dysfunction and related metabolic diseases. Meanwhile, the invention further provides a drug screening method, a treatment method and related drug application based on the regulation axis, systematic diagnosis and universal treatment of mitochondrial dysfunction related diseases are achieved, and the regulation axis has important clinical transformation value.

The invention relates to a neck vagus nerve stimulation device and a preparation method thereof. The neck vagus nerve stimulation device comprises a base body, an electrical stimulation unit and a drug delivery application. The electrical stimulation unit comprises a pulse generation module and an electrode connected with the pulse generation module, the electrode can release stimulation current to the skin of the human body, and at least the electrode is arranged on the base body. The drug delivery patch is arranged on the base body, and the drug delivery patch comprises a drug which can be absorbed through the skin. Wherein the base body is suitable for being attached to the neck skin of a human body, so that the electrodes and the administration application are in contact with the neck skin, and the electrical stimulation signals and the drug efficacy act on a target neck area through the neck skin. The neck vagus nerve stimulation device is compact in structure, portable, easy to use, low in cost and capable of enhancing the treatment effect.

The disadvantage of a coating-type microneedle is that it is difficult to coat a large amount of a drug on the microneedle, and thus the effective use of the drug is limited. The present invention eliminates the disadvantage of the coating-type microneedle. A drug application type microneedle array is characterized by comprising a substrate and a plurality of microneedles, and the microneedles are arranged on the substrate in such a manner that at least three microneedles form a group to form a space and thereby provide a drug application part in the space.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an MYC mRNA translation inhibitor in preparation of a medicine for preventing and / or treating osteoarthritis. The MYC mRNA translation inhibitor is selected from biological materials capable of inhibiting or blocking the MYC mRNA translation process, reducing the MYC protein synthesis efficiency or interfering the MYC mRNA steady state level. The invention provides a novel molecular target capable of being used for treating osteoarthritis and a medicine application scheme of the molecular target.

This invention relates to a cell-penetrating peptide Y119E and its application in inhibiting the growth of cisplatin-resistant tumors. The invention is characterized by using the cell-penetrating peptide TAT as a carrier to deliver a cell-penetrating peptide containing PGAM1 phosphorylated at position Y119 into tumor cells. The cell-penetrating peptide containing Y119 phosphorylated peptide (Y119E) has the sequence YGRKKRRQRRR-KIWRRSEDVP. The short cell-penetrating peptide Y119E is used in the drug application of inhibiting the growth of cisplatin-resistant tumors. It can effectively inhibit tumor growth subcutaneously in nude mice.

The application discloses a fundus blood vessel drug application region classification method based on a time sequence fusion network and relates to the technical field of medical image classification. Step one: after an image sequence and corresponding labels are acquired, an image labeling tool is used to convert the image and label information into a format suitable for neural network learning, and then a boundary box of a drug application region is drawn on the last image and the corresponding category is labeled; the fundus blood vessel drug application region classification method based on the time sequence fusion network, the application considers the characteristics of FFA image drug application region classification and proposes a time sequence fusion target detection network, a group of FFA images are input, the time sequence fusion target detection network can not only locate the drug application region but also extract time sequence information of the drug application region to provide a basis for classification. This not only makes up for the deficiency that a traditional target detection network cannot process sequence images, but also introduces a time sequence information extraction module to simulate an observation process of dynamic changes of a drug application region in an artificial classification process, so that the classification accuracy can be improved.

The invention belongs to the technical field of biological medicines, and discloses a CD28-targeted single-domain antibody, a coding gene and application thereof. The CD28-targeted single-domain antibody contains complementary determining regions CDR1, CDR2 and CDR3 which are respectively as shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, and the single-domain antibody has an amino acid sequence as shown in SEQ ID NO.4. The CD28-targeted single-domain antibody has the advantages that the CDR1, the CDR2 and the CDR3 are respectively as shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; the antibody is combined with Human-CD28 and has good reaction activity, a foundation is provided for research and development of CD28-targeted drugs, and the antibody has important significance in the fields of drug application, clinical detection and diagnosis and the like.

This invention provides a susceptibility gene for Th2-type asthma, a drug for it, and its application. The susceptibility gene is ALOX15, and the drug is an inhibitor of ALOX15 expression. This invention is the first to discover the relationship between ALOX15 and its main product, 15-HETE-PE, and Th2-type asthma. Inhibition of ALOX15 expression significantly reduces eosinophil expression and the number and percentage of eosinophils in blood and bronchoalveolar lavage fluid. Therefore, specific treatment targeting ALOX15 can serve as a novel treatment for asthma. The drug of this invention effectively reduces eosinophil count in animal and cell experiments, achieving a therapeutic effect for Th2-type asthma. This is a significant advantage compared to some refractory asthma patients whose eosinophil count cannot be reduced to normal levels with existing treatments.

To provide a hair parting structure and a drug application device having a hair parting structure, which is smaller in size and has less resistance to parting for a user with thick hair, is easy to insert into thick hair, and easily parts the hair, thereby improving the user's usage experience. The hair parting mechanism includes a main body 1 having a head 2 for parting hair, the head 2 being rod-shaped, with a cross-sectional dimension that gradually decreases along the length of the head 2, and a through-hole drilled in the main body 1. This solves the problem of high resistance to parting hair in the prior art.

The present application relates to a kind of safflower oil body in the preparation of preventing or treating intestinal inflammatory disease drug application, belong to the technical field of new use of material.The present application provides the new use of safflower oil body in medicine, i.e.safflower oil body is applied in the new drug of preventing and treating colitis and other inflammatory bowel disease.The present application is committed to the experimental research of safflower oil body preventing and treating colitis and other inflammatory bowel disease, and it is proved by mouse in-vivo experiment that safflower oil body has significant prevention and treatment effect on colitis and other inflammatory bowel disease.The present application has explored new medical use for safflower oil body, and developed a new natural medicine research field.Safflower oil body of the present application can be used as drug in the prevention and treatment of colitis, with good physical and chemical stability, no toxic side effects, and good anti-inflammatory capacity and other advantages.

The application discloses an antibody, a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenamase, can reduce the carbapenam antibiotic resistance level of acinetobacter baumannii, thereby reducing the use concentration of meropenem in clinic, and improving the treatment effect of meropenem on acinetobacter baumannii. In addition, the antibody can also inhibit the OXA-23 protein secreted by bacteria, prevent the hydrolysis of carbapenam antibiotics by bacteria, increase the antibiotic concentration at a drug application site, and is favorable for clearing mixed infections with acinetobacter baumannii. The application provides a new strategy for treating acinetobacter baumannii infections, and has a wide application prospect.